NUCIEN PHARMA(SH:688189)2025-02-27 09:25Financial Performance - Total revenue for 2024 was CNY 27,398.33 million, a decrease of 63.20% compared to the previous year[4] - Operating profit for 2024 was CNY -39,189.22 million, a decline of 5,387.12% year-over-year[4] - Net profit attributable to shareholders of the parent company was CNY -35,423.77 million, down 9,542.56% from the previous year[4] - Basic earnings per share for 2024 were CNY -1.2910, a decrease of 9,523.36% compared to the previous year[4] - The weighted average return on net assets was -31.18%, a decrease of 31.47 percentage points compared to the previous year[4] Assets and Equity - Total assets at the end of 2024 were CNY 123,373.35 million, a reduction of 29.00% from the previous year[6] - Shareholders' equity attributable to the parent company was CNY 95,387.82 million, down 27.63% year-over-year[6] Strategic Adjustments - The company adjusted sales strategies and reduced prices for core products due to industry policy changes and increased market competition[7] - The company implemented cost reduction measures, resulting in a significant decrease in selling, administrative, and financial expenses compared to the previous year[7] Report Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[9]